Given the limited treatment options for diastolic dysfunction and galectin-3’s importance in cardiovascular diseases, investigating its role offers promise for enhancing risk assessment and guiding therapeutic strategies. The gene discussed is LGALS3; the disease is cardiovascular disorder.